Company Filing History:
Years Active: 1995-2003
Title: Irwin H Gelman: Innovator in Tumor Suppressor Gene Research
Introduction
Irwin H Gelman is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of molecular biology, particularly in the area of tumor suppressor genes. With a total of 3 patents, Gelman's work has implications for both diagnostic and therapeutic methods in cancer research.
Latest Patents
One of Gelman's latest patents involves a novel tumor suppressor gene known as SSeCKS. This gene product serves as a substrate of protein kinase C and functions as a mitogenic regulator, as well as an inhibitor of the transformed phenotype. The invention emphasizes the importance of the SSeCKS gene and protein, particularly in rat and human models. Another patent also focuses on the SSeCKS gene, which was previously referred to as '322'. This gene was found to be down-regulated in certain transformed cells, further establishing its role in cancer biology.
Career Highlights
Throughout his career, Gelman has worked with esteemed institutions such as Mount Sinai School of Medicine and The Rockefeller University. His research has been pivotal in advancing our understanding of tumor suppressor mechanisms.
Collaborations
Gelman has collaborated with notable colleagues, including Stephen S Morse and Hidesaburo Hanafusa. These partnerships have enriched his research and contributed to the scientific community's knowledge of cancer biology.
Conclusion
Irwin H Gelman's innovative work in tumor suppressor genes has made a lasting impact on cancer research. His patents and collaborations continue to influence the field, paving the way for future advancements in diagnostics and therapies.